Clinical Trial Update: Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update comparing one-month versus three-month paliperidone palmitate treatment in schizophrenia, across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone palmitate (Paliperidone palmitate)

Snippet

Sponsor: Calo Psychiatric Center | Conditions: Schizophrenics | Phase 1, Phase 2 | Status: COMPLETED